Has there been progress in the treatment of older patients with acute myeloid leukemia?

Published

Journal Article (Review)

The treatment of older patients with acute myeloid leukemia (AML) has become increasingly important as the population ages. Progress, measured by overall survival rates, has improved in younger patients, perhaps due to the use of intensive post-remission therapies, but it is unclear what will enable progress for older AML patients. The older AML patient population is very heterogeneous, and both patient-specific and leukemia-specific factors must be taken into consideration when choosing the therapy that will most benefit each patient. In addition to standard and intensive chemotherapy regimens, a number of alternative therapies for previously untreated older AML patients are currently being investigated. These include gemtuzumab ozogamicin, azacitidine, decitabine, and clofarabine.

Full Text

Duke Authors

Cited Authors

  • Erba, HP

Published Date

  • December 2010

Published In

Volume / Issue

  • 23 / 4

Start / End Page

  • 495 - 501

PubMed ID

  • 21130413

Pubmed Central ID

  • 21130413

Electronic International Standard Serial Number (EISSN)

  • 1532-1924

Digital Object Identifier (DOI)

  • 10.1016/j.beha.2010.09.012

Language

  • eng

Conference Location

  • Netherlands